Trials / Terminated
TerminatedNCT01420081
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
A RANDOMIZED PHASE 2 NON-COMPARATIVE STUDY OF THE EFFICACY OF PF-04691502 AND PF-05212384 IN PATIENTS WITH RECURRENT ENDOMETRIAL CANCER
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.
Detailed description
The study was prematurely discontinued due to lack confidence in the Stathmin assay as a patient selection criteria and subsequent lack of confidence in the efficacy signal that was observed. The decision to terminate the study was made on January 23, 2014. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-05212384 | 154mg IV weekly |
| DRUG | PF-05212384 | 154mg IV weekly |
| DRUG | PF-05212384 | 154mg IV weekly |
Timeline
- Start date
- 2012-01-19
- Primary completion
- 2014-04-30
- Completion
- 2015-12-25
- First posted
- 2011-08-19
- Last updated
- 2019-01-08
- Results posted
- 2015-05-19
Locations
51 sites across 8 countries: United States, Australia, Canada, Japan, Poland, Russia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01420081. Inclusion in this directory is not an endorsement.